Filing Analysis
DocGo Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Most notably, stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-10, to be determined by the Board.
🚩 Red Flags
- Approval of a reverse stock split is a major red flag for micro-cap companies, often indicating a struggle to maintain minimum exchange listing price requirements.
- Significant 'Votes Withheld' for director nominees (e.g., 25.1M withheld for James M. Travers), suggesting shareholder dissatisfaction.
📋 Key Facts
- Stockholders approved a reverse stock split with a ratio range of 1-for-5 to 1-for-10.
- Vina Leite and James M. Travers were elected as Class II directors.
- Executive compensation was approved on a non-binding, advisory basis.
- Urish Popeck & Co., LLC was ratified as the independent registered public accounting firm for 2026.
- The 'Corporate Opportunity Amendment' and 'Officer Exculpation Amendment' were both rejected by stockholders.
DocGo Inc. announced its financial results for the first quarter ended March 31, 2026. The company furnished a press release and non-GAAP financial reconciliations, specifically highlighting adjusted gross margin.
📋 Key Facts
- Earnings results for the quarter ended March 31, 2026, were announced on May 11, 2026.
- The company reported non-GAAP 'adjusted gross margin' and provided a reconciliation to GAAP measures in Exhibit 99.2.
- A conference call was held on May 11, 2026, at 5:00 p.m. ET to discuss the results.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
DocGo Inc. announced the resignation of director Dr. Stephen K. Klasko and a subsequent board reshuffle, including the appointment of Michael Burdiek as independent Chair. Crucially, the company also formed a special committee dedicated to identifying cost reductions and corporate efficiencies to accelerate profitability.
🚩 Red Flags
- The formation of a special committee specifically for 'cost reduction' and 'efficiencies' often signals internal or external pressure regarding the company's burn rate or path to profitability.
- Board reshuffling occurring simultaneously with the initiation of cost-cutting measures.
📋 Key Facts
- Dr. Stephen K. Klasko to resign from the Board effective June 16, 2026, to accept a new healthcare leadership role.
- Michael Burdiek appointed as independent Chair of the Board, effective June 16, 2026.
- Jim Travers appointed to the Audit and Compliance Committee and the Nominating and Corporate Governance Committee.
- A special committee was formed on April 21, 2026, consisting of Vina Leite, Ira Smedra, and Michael Burdiek (Chair).
- The special committee's mandate is to identify corporate efficiencies and cost reduction opportunities to accelerate profitability.
DocGo Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The company scheduled a conference call for March 16, 2026, to discuss these results and provided reconciliations for non-GAAP financial measures.
📋 Key Facts
- Earnings results cover the quarter and fiscal year ended December 31, 2025.
- The company reported the use of a non-GAAP financial measure, 'adjusted gross margin'.
- A conference call and webcast were scheduled for 5:00 p.m. Eastern Time on March 16, 2026.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Non-GAAP Financial Information).